Related Experiment Video
Updated: Apr 3, 2026
10:16
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
13.8K
Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.
Jamal Carter1, Li-Hui Tseng2, Gang Zheng1
1From the Departments of Pathology and.
American Journal of Clinical Pathology
|September 20, 2015
Summary
Next-generation sequencing (NGS) effectively detects BRAF mutations in various cancers, including lung, colorectal, and melanoma. This assay shows high sensitivity for identifying both common and novel BRAF alterations, crucial for understanding their clinical impact.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- BRAF mutations are key drivers in several cancers, including melanoma, lung adenocarcinoma, and colorectal cancer.
- Accurate detection of BRAF mutations is essential for guiding targeted therapy and understanding tumor biology.
- Next-generation sequencing (NGS) offers a comprehensive approach for analyzing genetic alterations in neoplastic tissues.
Purpose of the Study:
- To evaluate the performance of a next-generation sequencing (NGS) platform for the clinical detection of BRAF mutations.
- To assess the sensitivity and reportable range of the NGS assay for BRAF alterations.
- To characterize the spectrum of BRAF mutations, including non-p.V600E variants, across different cancer types.
Main Methods:
- Retrospective quality assessment of an NGS assay.
- Analysis of BRAF mutations in exons 11 and 15 from 835 neoplastic tissue samples.
- Detection and characterization of BRAF mutations and their allele frequencies.
Main Results:
- NGS detected BRAF mutations in 5.9% of lung adenocarcinomas, 13% of colorectal cancers, and 44% of melanomas.
- Mutant allele frequencies below 20% were observed in 28% of BRAF-mutated specimens, with some as low as 1-2%.
- 39% of BRAF mutations were located outside codon 600, with lung adenocarcinomas showing a higher prevalence of non-p.V600E mutations (86%).
Conclusions:
- The NGS assay demonstrated high analytic sensitivity and a broad reportable range for clinical BRAF mutation detection.
- The study identified 26 unique BRAF mutations, including three novel ones, highlighting the assay's capability.
- Understanding the spectrum of non-p.V600E BRAF mutations is a critical step towards elucidating their clinical significance in various malignancies.
